Roche’s Multiple Sclerosis Drug Candidate Fenebrutinib Meets Main Goal in Late-Stage Trial

Swiss drugmaker Roche announced that its experimental multiple sclerosis treatment, Fenebrutinib, achieved its primary goal in a late-stage clinical trial by significantly reducing annual relapse rates...